When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
The U.S. Preventive Services Task Force (USPSTF) recently reversed its position that annual skin screenings are recommended for all adults, citing that the “current evidence is insufficient and…
Many cancer patients are not geographically-situated near the cancer care centers that offer them the best chances of recovery or survival. This is one of the many reasons…
Active surveillance of low- and mid-risk prostate cancer is becoming a widely accepted alternative to quickly administering more aggressive forms of therapy upon diagnosis. Educating patients on the…
Epstein-Barr virus (EBV), similar to other common viruses, remains in the body indefinitely after exposure and requires constant monitoring by the immune system in order to effectively to…
Precision medicine aims to tailor medical treatments to each patient’s individual genetic profile and biology. Cancer researchers know that patients with particular mutations may respond better to certain…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
